#United States #San Diego #PleoPharma #PP-01 #Cannabis Disorder

PleoPharma, Inc. to Present at BIO International Convention 2026

PleoPharma, Inc., a firm specializing in clinical development focused on combating cannabis-related health issues, is set to participate in the upcoming BIO International Convention. Scheduled for June 22-25, 2026, at the San Diego Convention Center, this prestigious event will provide a platform for key industry leaders to share their latest findings and innovations in biotechnology.

On June 23 at 12:15 PM in Theater 4, Chief Business Officer Jason Goodson will present an overview of PleoPharma's recent advancements, particularly focusing on their lead investigational product, PP-01. This treatment aims to assist those grappling with Cannabis Use Disorder (CUD) by alleviating withdrawal symptoms associated with reducing or ceasing cannabis use.

Understanding Cannabis Use Disorder

Cannabis Use Disorder is a significant and complex condition currently affecting an estimated 20.6 million individuals across the United States. As awareness of cannabis addiction grows, so does the number of people seeking treatment; in fact, over 1.4 million individuals were treated for CUD in 2024 alone. However, despite this critical need, there is currently no approved medication to ease the transition away from cannabis, exemplifying the urgent demand for effective solutions.

Many struggling with CUD report a rapid onset of severe withdrawal symptoms that emerge when they attempt to reduce or quit cannabis. Commonly experienced symptoms can include heightened anxiety, irritability, cravings, sleep disturbances, and even severe mood shifts, which often lead to relapses.

The Promise of PP-01

The investigational product PP-01 represents a breakthrough in treatment for individuals dealing with cannabis withdrawal symptoms. Designed to employ a dual mechanism of action, PP-01 targets the body's cannabinoid receptors, specifically suppressing CB1 receptors, while addressing neurotransmitter imbalances in the mesolimbic reward pathway. This could potentially set PP-01 apart as the first-class treatment for eliminating the distressing withdrawal symptoms that many individuals face when they stop using cannabis.

Currently in Phase 3 clinical trials, PP-01 is envisioned as a once-daily oral medication with a rapid onset of action, indicating an innovative approach with a focus on safety and tolerability. A significant milestone was reached recently as the first patient was dosed in this trial.

Engaging During the Convention

Those interested in connecting with PleoPharma to discuss potential collaborations or to learn more about their innovations in cannabis therapeutics can request meetings through the BIO Partnering™ system or reach out directly to Jason Goodson via provided contact channels.

About PleoPharma

PleoPharma is dedicated to addressing the challenges that come with cannabis addiction through their advanced research and development efforts. The company's leadership team is composed of experts celebrated for their success in managing high-stakes pharmaceutical projects, having achieved over 50 product approvals globally alongside numerous Investigational New Drug (IND) applications.

PleoPharma is committed to transforming the landscape of cannabis addiction treatment, and their showcase at the BIO International Convention 2026 symbolizes an important step toward this goal.

For more details on PleoPharma and their initiatives, visit their official website at www.PleoPharma.com or contact Brendi Bluitt for media inquiries.